Biron P, Droz J P
Département de cancérologie médicale, centre Léon-Bérard, Lyon, France.
Bull Cancer. 1995;82 Suppl 1:53s-55s.
High-dose chemotherapy with autologous bone-marrow transplantation is active in non-Hodgkin lymphoma patients. The results of randomized trials in the setting of consolidation of first complete remission are not in favor of use of high-dose chemotherapy. However preliminary results of pilot studies are in favor of this treatment in reponder patients. The results of the PARMA protocol will help to answer the question.